title: Pharmacokinetics and pharmacodynamics of clemastine in healthy horses.
abstract: Clemastine is an H1 antagonist used in certain allergic disorders in humans and tentatively also in horses, although the pharmacology of the drug in this species has not yet been investigated. In the present study we determined basic pharmacokinetic parameters and compared the effect of the drug measured as inhibition of histamine-induced cutaneous wheal formation in six horses. The most prominent feature of drug disposition after intravenous dose of 50 microg/kg bw was a very rapid initial decline in plasma concentration, followed by a terminal phase with a half-life of 5.4 h. The volume of distribution was large, Vss = 3.8 L/kg, and the total body clearance 0.79 L/h kg. Notably, oral bioavailability was only 3.4%. There was a strong relationship between plasma concentrations and effect. The effect maximum (measured as reduction in histamine-induced cutaneous wheal formation) was 65% (compared with controls where saline was injected) and the effect duration after i.v. dose was approximately 5 h. The effect after oral dose of 200 microg/kg was minor. The results indicate that clemastine is not appropriate for oral administration to horses because of low bioavailability. When using repeated i.v. administration, the drug has to be administered at least three to four times daily to maintain therapeutic plasma concentrations because of the short half-life. However, if sufficient plasma concentrations are maintained the drug is efficacious in reducing histamine-induced wheal formations.
authors.affiliation: Department of Pharmacology and Toxicology, SLU, BMC, SE-75123, Uppsala, Sweden. karolina.torneke@mpa.se
authors.forename: K
authors.initials: K
authors.lastname: Törneke
authors.forename: C
authors.initials: C
authors.lastname: Ingvast-Larsson
authors.forename: K
authors.initials: K
authors.lastname: Pettersson
authors.forename: K
authors.initials: K
authors.lastname: Bergvall
authors.forename: M
authors.initials: M
authors.lastname: Hedeland
authors.forename: U
authors.initials: U
authors.lastname: Bondesson
authors.forename: H
authors.initials: H
authors.lastname: Broström
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002974:Clemastine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D018592:Cross-Over Studies; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D006736:Horses / Q000378:metabolism*; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male
chemical_list: D006634:Histamine H1 Antagonists; D002974:Clemastine